tbuckley/cabot-search huggingface dataset:
Damage Induced in Sarcoma 37 with Chemical Agents. IV. Derivatives of Colchiceinamide
Authors: J. Leiter, J. L. Hartwell, I. Kline, M. V. Nadkarni, M. J. Shear
Journal: JNCI Journal of the National Cancer Institute (1952)

Journal Article Damage Induced in Sarcoma 37 with Chemical Agents. IV. Derivatives of Colchiceinamide Get access J. Leiter, J. Leiter Search for other works by this author on: Oxford Academic PubMed Google Scholar J. L. Hartwell, J. L. Hartwell Search for other works by this author on: Oxford Academic PubMed Google Scholar I. Kline, I. Kline Search for other works by this author on: Oxford Academic PubMed Google Scholar M. V. Nadkarni, M. V. Nadkarni Search for other works by this author on: Oxford Academic PubMed Google Scholar M. J. Shear M. J. Shear Laboratory of Chemical Pharmacology, National Cancer Institute3Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 13, Issue 3, December 1952, Pages 731–739, https://doi.org/10.1093/jnci/13.3.731 Published: 01 December 1952 Article history Received: 12 August 1952 Published: 01 December 1952
Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms
Authors: Marito Araki, Yinjie Yang, Nami Masubuchi, Yumi Hironaka, Hiraku Takei, Soji Morishita, Yoshihisa Mizukami, Shin Kan, Shuichi Shirane, Yoko Edahiro, Yoshitaka Sunami, Akimichi Ohsaka, Norio Komatsu
Journal: Blood (2016)
Migration-related tuberculosis: epidemiology and characteristics of tuberculosis cases originating outside the European Union and European Economic Area, 2007 to 2013
Authors: Csaba Ködmön, Phillip Zucs, Marieke J. van der Werf
Journal: Eurosurveillance (2016)

Migrants arriving from high tuberculosis (TB)-incidence countries may pose a significant challenge to TB control programmes in the host country. TB surveillance data for 2007-2013 submitted to the European Surveillance System were analysed. Notified TB cases were stratified by origin and reporting country. The contribution of migrant TB cases to the TB epidemiology in EU/EEA countries was analysed. Migrant TB cases accounted for 17.4% (n = 92,039) of all TB cases reported in the EU/EEA in 2007-2013, continuously increasing from 13.6% in 2007 to 21.8% in 2013. Of 91,925 migrant cases with known country of origin, 29.3% were from the Eastern Mediterranean, 23.0% from south-east Asia, 21.4% from Africa, 13.4% from the World Health Organization European Region (excluding EU/EEA), and 12.9% from other regions. Of 46,499 migrant cases with known drug-susceptibility test results, 2.9% had multidrug-resistant TB, mainly (51.7%) originating from the European Region. The increasing contribution of TB in migrants from outside the EU/EEA to the TB burden in the EU/EEA is mainly due to a decrease in native TB cases. Especially in countries with a high proportion of TB cases in non-EU/EEA migrants, targeted prevention and control initiatives may be needed to progress towards TB elimination.
SAT0491 Gender Specific Comorbidities in Juvenile Idiopathic Arthritis Patients: Table 1
Authors: G. Horneff, K. Minden, H.I. Huppertz, K. Tenbrock, J.-P. Haas
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Comorbidities can have a significant influence on presentation, course and prognosis of JIA. <h3>Objectives</h3> The aim of this study is to analyse the occurrence of comorbidities in a large JIA cohort. <h3>Methods</h3> JIA patients starting treatment with biologics or methotrexate were followed by the BIKER registry. This database was screened for comorbid conditions reported at baseline. Differences were analyzed by χ<sup>2</sup> test. <h3>Results</h3> 3427 pts (67.6% female) were admitted. The median [IQR] age at onset was 7.1 y. [3.1; 11.3], at inclusion was 11.8 y. [7.3-14.9] and the median disease duration was 2.1 y. [0,7-5.2]. 1517 (44.3%) pts started MTX. 1916 (55.7%) pts started a biologic. A total of 1327 comorbidities were reported in 959 pts (up to 4 per pts). Uveitis (327) was the most common followed by asthma (53), short stature (47), atopic dermatitis (44), Hashimoto thyreoiditis (29), obesity (28), heart defects (20), arterial hypertension (20), Psoriasis (25), pain amplification syndrome (19), attention-deficit hyperactivity disorder (19), diabetes mellitus type 1 (18), epilepsies (14) and cushingoid syndrome (14). Thus with the exception of uveitis, comorbidities are rarely reported. On interest, the rate of obesity reported is the same as the rate calculated (BMI SDS&gt;3 according to WHO), the rate of short stature reported is much lower than calculated (n=234, length SDS &lt;-2). Significant differences in gender distribution were noted for a number of comorbidities (table). Pts with hip dysplasia, Raynaud9s, and those suffering from macrophage activation syndrome were all female. For patients with systemic JIA especially short stature, hypertension, cushingoids, cataract, osteoporosis, celiac disease and MAS, in RF+ polyJIA osteoporosis and anaemia, in ext/pers. oligo JIA uveitis, in ERA attention deficit disorder and CRMO and in PsA asthma, Hashimoto9s and psoriasis were reported at least 2 fold more frequently than average. <h3>Conclusions</h3> Apart from uveitis comorbidities are rare, but there were marked gender related differences. Gender specific aspects should be taken into account considering the diagnostics and treatment of JIA. The limitation of these analyses is the voluntary reporting of comorbidities in BIKER. <h3>Disclosure of Interest</h3> None declared
Genomic Architecture and Treatment Response In Pediatric Acute Myeloid Leukemia: A Report From The Children’s Oncology Group
Authors: Marijana Vujkovic, Edward F. Attiyeh, Rhonda E. Ries, Michelle Horn, Elizabeth K. Goodman, Todd A. Alonzo, Robert B. Gerbing, Alan S. Gamis, Soheil Meshinchi, Richard Aplenc
Journal: Blood (2013)
SP0097 What is New: Osteoporosis &amp; Bone Diseases
Authors: F. Buttgereit
Journal: Annals of the Rheumatic Diseases (2015)

The aim of this talk is to provide insights into recent advances in the fields of secondary osteoporosis and emerging anti-osteoporotic therapies. There are several diseases and medications which may cause <i>secondary osteoporosis</i>. Among most prominent causes are rheumatic diseases such as rheumatoid arthritis, ankylosing spondylitis, but also polymyalgia rheumatica and giant cell arteritis (GCA). For example, new study data demonstrate a clear association between GCA and several conditions known to be related to glucocorticoid use including osteoporosis. As a matter of fact, glucocorticoids remain to be among the most important and most frequently used anti-inflammatory and immunosuppressive or immune-modulatory acting drugs to treat rheumatic (and other) diseases. And indeed, glucocorticoids also exert undesired effects, especially if higher dosages have to be given over longer periods of time. In this regard, <i>glucocorticoid-induced osteoporosis (GIOP)</i> and other adverse effects are to be mentioned here. However, the available data describing frequency and severity of these adverse effects are fragmentary. For example, it is difficult to distinguish specific adverse effects of a glucocorticoid therapy from other causations (e. g., the treated disease itself, other concomitant diseases or concomitant therapies). This statement is especially true for GIOP in the context of chronic inflammatory rheumatic diseases. Current anti-osteoporotic therapies mainly consist of medications such as bisphosphonates, denosumab, selective estrogen receptor modulators and teriparatide. However, there are promising drugs currently in development which use the recent advances in our knowledge of bone biology. Examples to be discussed here comprise both antiresorptive medications such as cathepsin-K inhibitors (odanacatib) and anabolic agents such as antisclerostin monoclonal antibodies (romosozumab and blosozumab) or PTHrp 1-34 (abaloparatide). <h3>Disclosure of Interest</h3> None declared
Feasibility of surveillance resistance to antituberculosis drugs :Europe, 1997
Authors: V Schwoebel, D Antoine, J Veen
Journal: Eurosurveillance (2000)

Between 28% and 100% of isolates from ten countries from the EuroTB network in 1997 were reported with data on antituberculosis drug susceptibility. Drug resistance was commoner among foreign-born patients and in general among patients who had been treate
AB0074 Interleukin-23 in Serum of Patients with Antineutrophil Cytoplasmic Antibody- Associated Systemic Vasculitis: Table 1.
Authors: T.V. Beketova, E.N. Aleksandrova, N.O. Nikonorova, E.L. Nasonov
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> There is probably a systemic shift of cytokine production in patients with antineutrophil cytoplasmic antibody (ANCA)- associated systemic vasculitis (AAV) toward the Th17 cytokine response. We investigated whether interleukin-23 (IL-23), Th17- related cytokine, have any correlations with disease activity, clinical manifestations and treatment in AAV. <h3>Objectives</h3> To analyse the concentration of interleukin-23 (IL-23) in serum of AAV patients, compared with healthy controls (HC). <h3>Methods</h3> An enzyme- linked immunosorbent assay (ELISA) was used to analyse the serum concentration of IL-23 in 40 patients with AAV (median age 44 yrs (20- 65); F:M=1,11) and 8 HC (median age 47 yrs (21- 66); F:M=1,67). 23 patients were classified as granulomatosis with polyangiitis (GPA), 14- microscopic polyangiitis (MPA), and 3- eosinophilic granulomatosis with polyangiitis (EGPA). 26 patients were examined in active phase, 28- in remission (in 22/28 remission was induced by rituximab). The correlations between the levels of IL-23 and disease activity, clinical parameters were analysed. <h3>Results</h3> The levels of IL-23 increased significantly in the serum of active PR3-ANCA patients before treatment compared with HC (median 41.9 pg/ ml and 13.1 pg/ ml, respectively, p&lt;0,05). As immunosuppressive and anti B cell therapy (rituximab) in AAV patients resulted in effective suppression of serum IL-23 (5,2- 8,8 pg/ ml). <h3>Conclusions</h3> There is a prospect further study of IL-23 and functionally similar cytokines in the pathogenesis of AAV. <h3>Disclosure of Interest</h3> None declared
KIT Mutation Versus MRD, Which Is More Important To Predict Relapse Of Acute Myeloid Leukemia With t (8; 21)?
Authors: Hong-Hu Zhu, Daihong Liu, Hao Jiang, Ya-Zhen Qin, Lan-Ping Xu, Qian Jiang, Xiao-Hui Zhang, Huan Chen, Jin Lu, Yu Wang, Li-Ru Wang, Jun-Yue Chai, Kai-Yan Liu, Bin Jiang, Xiao-Jun Huang
Journal: Blood (2013)
PWE-337 Prophylactic mesh use during primary stoma formation to prevent parastomal hernia: a systematic review and meta-analysis
Authors: J-B Cornille, I Daniels, S Pathak, NJ Smart
Journal: Gut (2015)

<h3>Introduction</h3> Parastomal herniation (PSH) is a common and debilitating problem following stoma formation, with up to 30% of patients requiring further surgical intervention. The optimal surgical technique for stoma formation is yet to be defined though recent randomised trials have focussed on whether prophylactic mesh placement at the time of stoma creation can reduce the rate of PSH. The aim of this study was to systematically review use of prophylactic mesh versus no mesh with regard to a) occurrence of PSH and b) peristomal complications. <h3>Method</h3> A literature search was performed using PubMed, Embase and the Cochrane Library databases to identify Randomised Control Trials (RCTs) that analysed placement of prophylactic mesh versus no mesh at time of initial surgery to prevent PSH. The primary outcomes of interest were PSH occurrence and peristomal complications. <h3>Results</h3> A total of 409 studies were identified by our search strategy. Six studies were included, involving 319 patients (158 mesh <i>vs</i>161 no mesh). Prophylactic mesh placement resulted in a significantly lower rate of PSH formation 15.2% (23/151) <i>versus</i>40.6% (63/155), with a combined risk ratio was 0.39 (95% CI, 0.20 to 0.77, P = 0.007). Placement of prophylactic mesh did not result in increased peristomal complications (7% (11/157) versus 2% (9/160) with a combined risk ratio of 1.23(95% CI, 0.53 to 2.85, P = 0.63). <h3>Conclusion</h3> Prophylactic placement of mesh at primary stoma formation appears to reduce the incidence of PSH, without an increase in peristomal complications. <h3>Disclosure of interest</h3> None Declared.
Investigation of a large outbreak of Clostridium difficile PCR-ribotype 027 infections in northern France, 2006-2007 and associated clusters in 2008-2009
Authors: G Birgand, K Blanckaert, A Carbonne, B Coignard, F Barbut, C Eckert, B Grandbastien, Z Kadi, P Astagneau
Journal: Eurosurveillance (2010)

In 2006 and 2007, a large outbreak of Clostridium difficile infections (CDIs) with PCR-ribotype 027 was identified in northern France. Overall, 38 healthcare facilities notified 529 CDIs over a 22-month period, including 281 laboratory-confirmed CDI 027 and 248 non-confirmed CDI 027 cases (incidence rate per 10,000 elective bed days: 1.63, range: 0.07 to 7.94). The cases occurred mainly in long-term care hospital facilities and nursing homes, near the border between France and Belgium. An active surveillance and prevention campaign was launched at the first epidemic peak including hygiene precautions for healthcare professionals, which supported healthcare facilities to improve care organisation. The outbreak was controlled at the end of 2007, but sporadic cases were identified until the end of 2009. A bundle of appropriate control measures may halt the spread of such outbreaks, provided that substantial human resources and financial support are available.
Treatment of gastric leaks after sleeve gastrectomy
Authors: Lionel Rebibo, Richard Delcenserie, Franck Brazier, Thierry Yzet, Jean-Marc Regimbeau
Journal: Endoscopy (2016)

It is with great interest that we read the article entitled “Endoscopic treatment of fistula after sleeve gastrectomy: results of a multicenter retrospective study” [1], concerning the endoscopic management of gastric leakage after laparoscopic sleeve gastrectomy (LSG).
Screening for Gestational Diabetes Mellitus
Authors: H W Kaufman
Journal: New England Journal of Medicine (1998)

Gestational diabetes occurs in 3 to 6 percent of pregnancies and is associated with increased rates of macrosomia, serious birth trauma and cesarean section. Neonatal hyperbilirubinemia, hypocalcemia and hypoglycemia also occur more frequently in this disorder. Perinatal outcome is improved through the identification and management of affected women. It is therefore recommended that all pregnant women be screened for this condition at 24 to 28 weeks of gestation. In addition to plasma glucose levels, a new measurement of glycemic control--the serum fructosamine level--may prove useful in identifying and managing women with gestational diabetes.
FRI0272 Five Factor Score (FFS) and its Relationship with Mortality in Granulomatous Poliangiitis (GPA)
Authors: O. Karadag, L. Kilic, A. Erden, I. Dogan, U. Kalyoncu, S. Kilickap, A. Akdogan, S.A. Bilgen, S. Kiraz, I. Ertenli
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Five Factor Score (FFS) has been used in evaluating prognosis in systemic vasculitis including GPA. A revised FFS was published in 2011.<sup>1</sup> <h3>Objectives</h3> This study is aimed to investigate usefullness of revised FFS and its relationship with mortality in GPA. <h3>Methods</h3> Totally 77 (F/M: 41/36) GPA patients from database of Vasculitis center was retrospectively analyzed. Demographic and clinical characteristics were recorded. Five factor score of patients were calculated. Patients who had been lost from follow up was evaluated by phone call (n=14). Survival analysis was done by Kaplan-Meier method. <h3>Results</h3> Mean ages of patients were 50±15 years. Distribution of organ involvements were as; ear-nose –throat (ENT): 81.7%, pulmonary: 83.3%, renal: 59.5%, skin: 32.4%, musculoskeletal: 68.6%, eye: 23.3%. ANCA was positive in 74% of patients (cANCA/ pANCA:65%/14.7%). Most frequent treatment protocol in remission induction was corticosteroid + cyclophosphamide (75.5%). Rituximab was used in 12 (15.6%) patients. Seven of patients with renal involvement (n=23) were died, whereas three patients had renal transplantation and four had been on hemodialysis therapy. Totally 14 patients had died. Causes of mortality were co-infections in chronic renal failure (n=2), pulmonary hemorrhage (n=3), pulmonary hemorrhage and infection (n=2), gastrointestinal perforation (n=2), infective endocarditis (n=1), not known (n=4). Survival analysis was done with 63 patients. Median survival time was 36 (1-264) months. One-year and three-year survival rate was 92% and 81%, respectively. Twenty-three (36.5%) of patients had follow-up ≥5 years. Survival rate was statistically different between groups regarding to FFS scores (Table, p=0.003, Figure). 3-year survival rate was higher in patients with ENT involvement compared to without (87% vs 58%, p=0.052). <h3>Conclusions</h3> Three-year survival rate of GPA patients in our Vasculitis center is 81%. Survival rate was lower in patients with higher FFS scores concordant with literature. According to our results, FFS was found useful in evaluating prognosis in GPA. <h3>References</h3> Guillevin L ve ark. The Five Factor Score revisited. Medicine 2011; 90:19-27. <h3>Disclosure of Interest</h3> None declared
AB0072 Association of the a Allele of the TNF Alpha-308 G/A Gene Polymorphism with the Activity of MMP-9 in the Plasma and Synovial Fluid of Patients Suffering from Rheumatoid Arthritis
Authors: S.K. Stojanovic, B.N. Stamenkovic, J. Nedovic, S. Milenkovic, V. Skakic, T. Jevtovic Stoimenov
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Proteolytic enzymes – Matrix Metalloproteinases (MMP), have a significant role in the process of bone and cartilage destruction in rheumatoid arthritis (RA). <h3>Objectives</h3> Examination of the influence of the TNF-α gene polymorphism on the production of MMP-9 in the plasma (PL) and synovial fluid (SF) of patients suffering from RA. <h3>Methods</h3> The examination included 72 patients with early RA and knee synovitis, receiving methotrexate therapy. RA diagnosis was established within 6 months from the onset of symptoms, based on the ACR/EULAR criteria from 2010. The control group comprised 25 examinees with knee osteoarthrosis (OA), who were comparable with the RA group according to their demographic characteristics (Table 1). The -308 G/A gene polymorphism for TNF alpha was determined for all patients using the PCR-RFLP method. With regards to the presence of the A allele of the examined polymorphism, the patients were divided into two subgroups: subgroup A (G/A and A/A genotypes) and subgroup G (G/G genotype). The activity of MMP-9 was measured in PL and SF of all examinees using the sandwich enzyme-linked immunosorbent assay (ELISA) method, according to the instructions provided by the manufacturer (Amersham Biosciences, Little Chalfont, Great Britain). Statistical calculations were performed in the SPSS program, version 15.0 <h3>Results</h3> The activity of MMP-9 in PL and SF of the patients with RA is statistically significantly greater than the activity of this enzyme in PL and SF of the control group patients, with the statistically more significant difference (p&lt;0.001) determined for the activity of MMP-9 in SF (15.07±13.24 to 0.65±0.41 ng/ml) in relation to the activity of this enzyme in PL (18.28±7.54 to 13.58±3.07 ng/ml), (p&lt;0.01). Within the group of patients where the activity of MMP-9 in PL and SF was determined, 37 (51.39%) examinees belonged to Group A, while 35 (48.61%) belonged to Group G. A higher activity of MMP-9 both in PL and SF was registered in Group A than in Group G, with the statistical significance reached only for the activity of MMP-9 in SF (Table 2). <h3>Conclusions</h3> The activity of MMP-9 in the plasma and synovial fluid of RA patients is greater than the activity of this enzyme in PL and SF of examinees with osteoarthrosis. The presence of the A allele of the TNF-α -308 G/A gene polymorphism is associated with the increased activity of MMP-9 enzyme in the synovial fluid of patients with early RA, and it can predict a faster radiological progression of the disease. <h3>Disclosure of Interest</h3> None declared
AB0638 Risk Factors and Onset of Renal Involvement in Children with Schoenlein Henoch Purpura
Authors: D. De Vivo, A. La Mazza, C. Fede, A. Vitale, C. Ventrici, G. Conti, C. Fede
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Henoch-Schöenlein purpura (HSP) is the most common vasculitis in children, characterized by multisystem involvement. Renal complication occurs in 30-40% of HSP children. It is the most serious complication in the chronic outcome. <h3>Objectives</h3> Objective of the study is to evaluate the possible risk factors of renal complications in our series of children with HSP. Moreover we have tried to determine the time of onset of renal involvement. <h3>Methods</h3> Retrospective study was conducted in children with HSP in our Department with follow-up of at least 24 months. We evaluated 66 children, 37 males and 29 females. We have considered as risk factors of renal complication the sex, the presence or history of allergy, the joint and intestinal involvement. <h3>Results</h3> 20/66 HSP children have showed renal involvement (RHSP). RHSP was more frequent in males (14/20: 70%) versus females (6/20: 30%). Among the 46 children without renal involvement 24 (52%) were male and 22 (48%) females. Our data show that the male has greater risk of developing renal complications (OR 2.13; 95% CI 0.69 to 6.54).Average age of onset of vasculitis is 75.5±24 months in the RHSP versus 72.1±33.6 months in HSP without renal involvement. There was no difference in joint (60% versus 63%) and/or bowel (50% versus 41%) involvement between the two groups. Allergic symptoms occurred in 15% of RHSP children versus 29% of HSP children without renal involvement. Renal involvement developed in 30% of cases at onset of HSP; in 60% within 10 days of the diagnosis, and in 90% within 6 months. Only two children had renal complication after 12 and 18 months from diagnosis. Six renal biopsies were performed: 3 at the onset of illness and 3 within ten days from HSP diagnosis. Cutaneous recurrences occurred more frequently in the HSP group without renal involvement (30%) than in RHSP (5%) (OR 8.3; 95% CI 1.01 to 68.33). <h3>Conclusions</h3> Our data showed that the male is the greater risk factor for renal complications in HSP patients. The renal involvement occurred mostly at onset and in the majority of cases within 6 months. In addition, the renal complication is more severe in the early days of onset of HSP as evidenced by the greater frequency of renal biopsies. We recommended to monitor carefully urine exam in the first 6 months from onset of vasculitis. Cutaneous relapses were rare in patients with RHSP, indicating a different pathogenetic mechanism and phenotypic expression between HSP patients. <h3>References</h3> Narchi H. Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child 2005;90:916–920. <h3>Disclosure of Interest</h3> None declared
Epirubicin and the risk of leukemia: not substantiated? International Collaborative Cancer Group Steering Committee.
Authors: M Marty
Journal: Journal of Clinical Oncology (1993)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1993.11.7.1431 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8369062 Epirubicin and the risk of leukemia: not substantiated? International Collaborative Cancer Group Steering Committee. M MartyxM MartySearch for articles by this author https://doi.org/10.1200/JCO.1993.11.7.1431 First Page PDF © 1993 by American Society of Clinical Oncology